Drugs / CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07143929 | Aug 2025 → Jul 2026 overdue | peripheral T-cell lymphoma, not otherwise specified | Peking University People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07143929 ↗ |
| Modality | Cell therapy | “CD7-targeted chimeric antigen receptor T cells” NCT07143929 ↗ |
| Target | CD7 | “CD7-targeted chimeric antigen receptor T cells” NCT07143929 ↗ |